Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 5/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 5/20 | 0.45 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405064 | 1.00 | DGAT2 (0.49) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29405937 | 0.91 | KLKB1 (0.48) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL22659168 | 0.91 | KLKB1 (0.48) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL22659373 | 0.89 | BRAF (0.47) | DGAT2HDAC4TRPV1DDR2MAPT | |
| SCHEMBL22659137 | 0.89 | KCNQ3 (0.47) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL22659842 | 0.87 | MCHR1 (0.51) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL22680062 | 0.85 | WNT3A (0.50) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL24571432 | 0.83 | NTRK1 (0.42) | DGAT2WNT3AMAPTGSK3BBRAF | |
| SCHEMBL22659169 | 0.82 | KCNJ11 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1TRPV1 | |
| SCHEMBL22679920 | 0.82 | TRPV1 (0.47) | DGAT2KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | DGAT2 1279/4885KCNQ3 4135/4885KCNQ2 4299/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | DGAT2 1279/4885KCNQ3 4135/4885KCNQ2 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.